Medicine & Life Sciences
Anticoagulants
100%
Dabigatran
94%
Rivaroxaban
68%
Thrombin
62%
Extracellular Vesicles
53%
Heparin
51%
Prothrombin Time
48%
Hemostasis
38%
apixaban
34%
Thrombocytopenia
32%
Blood Platelets
32%
Paroxysmal Hemoglobinuria
32%
Factor Xa Inhibitors
29%
Hemorrhage
29%
Protein-Tyrosine Kinases
29%
SARS Virus
28%
Thrombosis
25%
Thromboplastin
24%
edoxaban
24%
Partial Thromboplastin Time
24%
eculizumab
22%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
22%
Low Molecular Weight Heparin
21%
Thrombin Time
19%
Atrial Fibrillation
19%
ponatinib
19%
betrixaban
19%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
18%
Vaccination
17%
Dasatinib
17%
Vitamin K
16%
Vaccines
16%
Meta-Analysis
15%
Erythrocytes
15%
Thrombophilia
14%
Systematic Reviews
13%
Imatinib Mesylate
13%
Coronavirus
13%
Venous Thromboembolism
13%
Neutrophils
13%
Fibrinolysis
13%
Antibodies
13%
Multicenter Studies
12%
Therapeutics
12%
idarucizumab
11%
Fibrinogen
11%
Hemolysis
11%
Prospective Studies
11%
Nanostructures
10%
Chemical Compounds
Anticoagulant Agent
54%
Rivaroxaban
31%
Heparin
21%
Dabigatran
20%
Coagulation
20%
Dabigatran Etexilate
20%
Thrombin
18%
Plasma
18%
Low Molecular Weight Heparin
17%
Anticoagulant
16%
Time
15%
Antagonist
14%
Prothrombin
14%
Thrombotic
11%
Plasma Concentration
10%
Procoagulant
10%
Activated Partial Thromboplastin Time
10%
Dose
9%
Drug
9%
Warfarin
9%
Fondaparinux
7%
Thromboxane B2
6%
Cytogenetics
6%
Antithrombin
6%
Nanomaterial
5%
Nanoparticle
5%
Holder
5%
Serotonin
5%